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Summary
Background: Although granulocyte colony stimulating 
factor (G-CSF) mobilization is generally well tolerated by 
healthy donors, there is also a wide spectrum of adverse 
events associated with it. Among these events, rhab-
domyolysis in peripheral blood stem cell (PBSC) donors 
is very rare. In this paper, we present a first case of rhab-
domyolysis after administration of filgrastim for PBSC 
mobilization. Case Report: A 6-year-old donor received 
10 µg/kg/day filgrastim subcutaneously for 5 days. On the 
3rd day of filgrastim, the donor complained of bone pain; 
a single dose of paracetamol (250 mg) was given to re-
lieve pain. On the 4th day, she complained of bone pain, 
myalgia, and vomiting. On laboratory analysis, serum 
creatine phosphokinase was 1,095 U/l (40–226 U/l), LDH 
312 U/l (100–190 U/l), aspartate aminotransferase 85 U/l 
(0–40 U/l), potassium 3.3 mmol/l (3.6–5.1 mmol/l). Urine 
myoglobin was 110 ng/ml (<5 ng/ml). Rhabdomyolysis 
was suspected on clinical and laboratory findings. Clini-
cal manifestations regressed and the laboratory results 
returned to normal within three days after intravenously 
forced diuresis and potassium replacement. Stem cells 
were successfully harvested from peripheral blood on 
the 5th day of G-CSF therapy. Conclusion: Rhabdomy-
olysis is a rare but important adverse effect of G-CSF. 
 Allogeneic PBSC donors should be closely monitored 
with regard to rhabdomyolysis after G-CSF administra-
tion in the mobilization setting.
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Zusammenfassung
Hintergrund: Die Mobilisation von Blutstammzellen mit 
Granulozyten-Kolonie stimulierendem Faktor (G-CSF) 
ist für gesunde Spender im Allgemeinen gut verträg-
lich. Das Spektrum möglicher unerwünschter Neben-
wirkungen von G-CSF ist vielfältig. Eine Rhabdomyoly-
se tritt bei Spendern von peripheren Blutstammzellen 
(PBSC) äußerst selten auf. In der vorliegenden Arbeit 
stellen wir einen ersten Fall von Rhabdomyolyse nach 
der Gabe von Filgrastim zur Mobilisation der PBSC vor. 
Fallbericht: Eine 6-jährige Spenderin erhielt 5 Tage lang 
subkutan 10 µg/kg/Tag Filgrastim. Am 3. Tag der Filgras-
tim-Gabe klagte die Spenderin über Knochenschmerzen, 
die mit einer einzelnen Dosis Paracetamol (250 mg) be-
handelt wurden. Am 4. Tag klagte sie über Knochen-
schmerzen, Myalgie und Erbrechen. Bei der Laborana-
lyse waren die Serumwerte für Creatinin-Phosphokina-
se 1095 U/l (40–226 U/l), für LDH 312 U/l (100–190 U/l), 
für Aspartat-Aminotransferase 85 U/l (0–40 U/l) und für 
Kalium 3,3 mmol/l (3,6–5,1 mmol/l). Der Myoglobinwert 
im Harn betrug 110 ng/ml (<5 ng/ml). Aufgrund der kli-
nischen und labortechnischen Untersuchungen wurde 
eine Rhabdomyolyse vermutet. Drei Tage nach einer in-
travenös forcierten Diurese und einer Kaliumsubstitution 
bildeten sich die klinischen Erscheinungsformen zurück 
und die Laborwerte normalisierten sich. Die Stamm-
zellen konnten am 5. Tag der G-CSF-Therapie aus dem 
peripheren Blut entnommen werden. Schlussfolgerung: 
Die Rhabdomyolyse ist eine seltene, aber bedeutende 
unerwünschte Nebenwirkung der G-CSF-Mobilisation. 
Während der Mobilisierung mit G-CSF sollten allogene 
PBSC-Spender sorgfältig im Hinblick auf eine Rhabdo-
myolyse überwacht werden.
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Introduction
Granulocyte colony stimulating factor (G-CSF) has been 
considered as the standard mobilizing agent for peripheral 
blood stem cell (PBSC) donors. Mobilization with G-CSF is 
generally well tolerated by the healthy donor; however, there 
is also a wide spectrum of adverse events associated with it. 
Common manageable toxicities are bone pain, fever, and 
reversible elevations of alkaline phosphatase (ALP), lactate 
dehydrogenase (LDH), aspartate aminotransferase (AST), 
and uric acid. Rare but serious and life-threatening toxicities 
such as thrombosis, myocardial infarction, adult respiratory 
distress syndrome, and splenic rupture may also occur [1]. 
Among healthy individuals, three patients are known to have 
developed acute myeloid leukemia 1–5 years subsequent to 
G-CSF administration [2]. Consequently, in recent years, 
questions have been raised concerning the safety of G-CSF 
in this setting.
Rhabdomyolysis is a syndrome that involves damage and 
breakdown of skeletal muscle, resulting in the release of mus-
cle cell contents into the systemic circulation, in association 
with a number of clinical triggers across the age spectrum. 
It presents with a classic triad of muscle pain, weakness, and 
brown urine [3]. However, in a recent series, only 1 of 191 
pediatric patients presented with all findings [4]. Therefore, a 
careful history should be taken for exclusion of rhabdomyoly-
sis in the differential diagnosis. 
Rhabdomyolysis in PBSC donors associated with G-CSF 
mobilization is very rare. Previously, only two cases have been 
documented during mobilization with lenograstim [5]. In this 
paper, we report a 6-year-old allogeneic PBSC donor who de-
veloped rhabdomyolysis following mobilization with filgras-
tim.
Case Report
A 14-year-old female was diagnosed with acute myeloid leukemia. After 
receiving standard remission induction chemotherapy, she achieved the 
first complete remission of her leukemia. Thereafter, she received a con-
solidation course of chemotherapy composed of high dose cytosine arabi-
noside. Finally, she was scheduled for allogeneic stem cell transplantation 
from her HLA-matched 6-year-old sister; informed consent was received 
from the parent.
Prior to recruitment, the donor underwent a detailed physical and 
laboratory examination. Her previous history was unremarkable. All 
pediatric vaccines had been administered. There was no history of disease 
or drug use. Her physical examination, chest X-ray, electrocardiogram, 
complete blood counts, blood chemistry profile, and parameters of he-
mostasis were normal. Viral serology regarding hepatitis A, B, and C, Ep-
stein-Barr virus, herpes 1 and 2, cytomegalovirus, adenovirus, influenza 
virus, cocksackie, echo, varicella zoster, and human immunodefficiency 
virus were negative.
The donor received 10 µg/kg per dose of filgrastim (Neupogen™; 
Amgen-Roche, Thousand Oaks, CA, USA) subcutaneously once daily 
for 5 days. On the 3rd day of filgrastim, the donor complained of bone 
pain; paracetamol was given as a single dose (250 mg). On the 4th day 
of G-CSF administration, a central venous catheter was implanted in 
the subclavian region. The patient did not receive any additional drugs 
or anesthetics for catheter implantation. She complained of bone pain, 
myalgia, and vomiting 6–8 h after the catheter was placed, at which time 
she was reevaluated. Physical examination was unremarkable. Body tem-
perature, respiration rate, and blood pressure were within normal ranges. 
Urine was tea-colored. Laboratory analysis was as follows: serum creatine 
phosphokinase (CK) was 1,095 U/l (40–226 U/l), LDH 312 U/l (100–190 
U/l), AST 85 U/l (0–40 U/l), uric acid 8.5 mg/dl (2.6–8 mg/dl), and potas-
sium 3.3 mmol/l (3.6–5.1 mmol/l). The other serum biochemistry variables 
were within normal ranges. In complete blood count, hemoglobin was 
12.5 g/dl, white blood cell count 39,800/µl, and platelet count 350,000/µl. 
A peripheral blood smear revealed leukocytosis with a left shift. Urine 
myoglobin level was 110 ng/ml (normal range <5 ng/ml).
Rhabdomyolysis was suspected on clinical and laboratory examination 
evaluation, and intravenously forced diuresis with potassium replacement 
was initiated. Central venous pressure was closely monitored. After 12 h 
clinical findings resolved and serum CK level started to decrease. Sub-
sequently, the patient’s muscular symptoms improved, with laboratory 
values returning to normal after 3 days. G-CSF administration was con-
tinued after diagnosis of rhabdomyolysis and initiation of diuretic treat-
ment. Stem cells were appropriately harvested from peripheral blood on 
the 5th day of G-CSF therapy, and CK value did not increase after stem 
cell apheresis.
Discussion
Rhabdomyolysis is a syndrome that results from muscle in-
jury, lysis, and degeneration leading to the release of intra-
cellular contents into the blood and urine. Rhabdomyolysis 
may be associated with life-threatening complications, e.g. 
acute renal failure, cardiac arrhythmias, and disseminated 
intravascular coagulopathy. The mortality rate may still be 
as high as 8%. Therefore, to prevent rhabdomyolysis-associ-
ated severe complications, early diagnosis and therapy are 
crucial. Additionally, overall prognosis of rhabdomyolysis 
is favorable with early diagnosis and treatment. The devel-
opment of rhabdomyolysis is associated with a wide variety 
of diseases, injuries, medications, and toxins [6, 7]. Nearly 
80% of cases of rhabdomyolysis are drug-related [7]. It can 
also be an unusual complication of high-dose chemothera-
py and hematopoietic stem cell transplantation [8]. Several 
chemotherapy agents causing rhabdomyolysis have been 
previously reported [9–12]. However, the rhabdomyolysis in 
healthy allogeneic stem cell donors during PBSC mobiliza-
tion is extremely rare [5]. The criteria of rhabdomyolysis, 
i.e. a more than 5-fold increase of CK, were met in these 2 
cases. Additionally, there was no evidence of other diseases 
as a cause for rhabdomyolysis in these donors; in particular, 
viral causes such as adenovirus, cytomegalovirus, influenza 
virus, cocksackie, echo, herpes simplex, varicella zoster, or 
Epstein-Barr virus were not detected. Hence, there are two 
probable causes regarding rhabdomyolysis in our donor. 
One is that rhabdomyolysis is a direct adverse effect of fil-
grastim or paracetamol. The other is that rhabdomyolysis 
is secondary to the combined adverse effect of these two 
agents. On the other hand, we can not prove whether or not 
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central venous catheterization may have caused rhabdomy-
olysis in our case. There are a few cases of myoglobinuria, 
especially following cardiac catheterization [13, 14]. How-
ever, we could not find any report regarding rhabdomyoly-
sis associated with it.
Drug-induced rhabdomyolysis can occur by a primary di-
rect toxic effect on the myocyte function or by an indirect sec-
ondary effect that predisposes the myocyte to develop injury 
[15]. However, the exact mechanism of rhabdomyolysis caused 
by these agents is not clearly known. To our knowledge, para-
cetamol alone, despite its widespread use, has caused myopa-
thy in only 3 patients, one of whom suffered from hypersen-
sitivity-associated rhabdomyolysis; the remaining 2 had toxic 
paracetamol-induced rhabdomyolysis [16–18]. This is the first 
documented case of rhabdomyolysis after administration of 
filgrastim.
The frequency and severity of rhabdomyolysis after G-CSF 
and/or paracetamol remain unclear. Some cases with mild or 
moderate rhabdomyolysis may be undiagnosed during G-CSF 
administration if CK monitoring is not performed. However, 
severe rhabdomyolysis can be associated with life-threatening 
complications. Therefore, allogeneic stem cell donors should 
be closely monitored with regard to rhabdomyolysis after/dur-
ing G-CSF administration and following hemapheresis. If ris-
ing CK levels are observed during G-CSF mobilization associ-
ated with mild or moderate rhabdomyolysis, urgent treatment 
may be initiated without discontinuation of G-CSF.
Disclosure 
The authors declared no conflict of interest.
References
 1 Takeyama K, Ohto H: PBSC mobilization. Trans-
fus Apher Sci 2004;31:233–243. 
 2 Tigue CC, McKoy JM, Evens AM, Trifilio SM, 
Tallman MS, Bennett CL: Granulocyte-colony 
stimulating factor administration to healthy indi-
viduals and persons with chronic neutropenia or 
cancer: an overview of safety considerations from 
the Research on Adverse Drug Events and Reports 
Project. Bone Marrow Transplant 2007;40:185–192.
 3 Knochel JP: Rhabdomyolysis and myoglobinuria. 
Annu Rev Med 1982;33:435–443.
 4 Mannix R, Tan ML, Wright R, Baskin M: Acute 
pediatric rhabdomyolysis: causes and rates of renal 
failure. Pediatrics 2006;118:2119–2125.
 5 Schanz J, Wolf C, Koehler M, Maas JH, Meyer M, 
Neumeyer H, Legler TJ, Wulf G, Glass B, Truem-
per L, Riggert J: Rhabdomyolysis in allogeneic 
peripheral blood stem cell donors. Vox Sang 2004; 
86:263–265.
 6 Bagley WH, Yang H, Shah KH: Rhabdomyolysis. 
Intern Emerg Med 2007;2:210–218.
 7 Prendergast BD, George CF: Drug-induced rhab-
domyolysis: mechanisms and management. Post-
grad Med J 1993;69:333–336. 
 8 Jackson SR, Barnett MJ, Keller O, Nantel SH, Phil-
lips GL: Recovery from rhabdomyolysis after allo-
geneic BMT: report of a case with speculation on 
causation. Bone Marrow Transplant 1995;15:803–
804.
 9 Koeffler HP, Haskell CM: Rhabdomyolysis as a 
complication of 5-azacytidine. Cancer Treat Rep 
1978;62:573–574. 
10 Pugliese P, Danova M, Brugnatelli S, Piccolo G, 
Riccardi A, Ascari E: Acute rhabdomyolysis after 
high dose chemotherapy and circulating progenitor 
cell autografting for breast cancer. Haematologica 
2000;85:672. 
11 Margolis D, Ross E, Miller KB: Rhabdomyolysis 
associated with high-dose cytarabine. Cancer Treat 
Rep 1987;71:1325–1326. 
12 Tabata N, Tanaka R, Suga S, Mitani Y, Nakano T, 
Ido M, Azuma E, Ito M, Hamazaki M, Shiraishi T, 
Sakurai M: Rhabdomyolysis following administra-
tion of cyclophosphamide: a case report in a BMT 
recipient. Bone Marrow Transplant 1996;17:1167–
1169.
13 Donald TG, Cloonan MJ, Wilcken DE: Excretion 
of myoglobin in urine after cardiac catheterisation. 
Br Heart J 1978;40:1237–1242.
14 McComb JM, McMaster EA: Serum myoglobin 
after cardiac catheterisation. Br Heart J 1982;47: 
353–356.
15 Ellenhorn MJ: Ellenhorn’s Medical Toxicology, 
Diagnosis and Treatment of Human Poisoning, ed 
2. Baltimore, Williams and Wilkins, 1997.
16 Moneret-Vautrin DA, Guerin L, Kanny G, Flabbee 
J, Fremont S, Morriset M: Acetaminophen-induced 
rhabdomyolysis. Allergy 1990;54:1115–1116. 
17 Waakel RA, Davies HT, Williams JD: Toxic 
myocarditis in paracetamol poisoning. Br Med J 
1987;295:1097. 
18 Yang CC, Deng JF, Lin TJ: Pancytopenia, hyper-
glycemia, shock, coma, rhabdomyolysis, and pan-
creatitis associated with acetaminophen poisoning. 
Vet Hum Toxicol 2001;4:344–348.
